Benjamin West, MD
Radiation Oncology · McAllen, TXNPI 1376587220
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,043, more than ten times the $16 reported in 2019.
Across 70 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$191
- Daiichi Sankyo Inc.$176
- Tempus AI, Inc$101
- GSK$99
- Takeda Pharmaceuticals U.S.A., Inc.$77
- Karyopharm Therapeutics Inc.$68
- plus $741 from 27 others
What the payments were for
- Food & beverage$1,451100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $191 |
| Daiichi Sankyo Inc. | 8 | $176 |
| Tempus AI, Inc | 2 | $101 |
| GSK | 5 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Karyopharm Therapeutics Inc. | 3 | $68 |
| Lilly USA, LLC | 3 | $67 |
| Merck | 3 | $67 |
| Genentech USA, Inc. | 2 | $52 |
| Astellas Pharma US Inc | 2 | $43 |
| Bayer | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| Pfizer | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Sanofi | 2 | $31 |
| Genmab U.S., Inc. | 1 | $29 |
| Eisai Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $23 |
| Syndax Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Sirtex Medical Inc | 1 | $21 |
| Pharmaessentia USA Corporation | 1 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Geron Corporation | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Beone Medicines USA, Inc. | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Caris MPI, Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Epizyme, Inc. | 1 | $13 |
How this compares
$1,451 in reported general payments places this provider in the 65th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 11 | $100 |
| Ondansetron Hcl | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in McAllen
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Robert TimmermanDallas$77K
- Abhilasha PatelHouston$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.